AnaptysBio (ANAB) – Investment Analysts’ Weekly Ratings Changes
by Mitch Edgeman · The Markets DailySeveral analysts have recently updated their ratings and price targets for AnaptysBio (NASDAQ: ANAB):
- 10/4/2026 – AnaptysBio was downgraded by Wall Street Zen from “buy” to “hold”.
- 9/30/2026 – AnaptysBio had its price target lowered by JPMorgan Chase & Co. from $70.00 to $60.00. They now have an “overweight” rating on the stock.
- 9/26/2026 – AnaptysBio was upgraded by Wall Street Zen from “hold” to “buy”.
- 9/23/2026 – AnaptysBio had its price target lowered by Leerink Partners from $90.00 to $81.00. They now have an “outperform” rating on the stock.
- 9/22/2026 – AnaptysBio had its “buy” rating reaffirmed by HC Wainwright. They now have a $95.00 price target on the stock.
- 9/22/2026 – AnaptysBio had its “overweight” rating reaffirmed by Cantor Fitzgerald.
- 8/31/2026 – AnaptysBio had its “outperform” rating reaffirmed by Wolfe Research. They now have a $78.00 price target on the stock.
- 8/25/2026 – AnaptysBio had its price target lowered by TD Cowen from $75.00 to $70.00. They now have a “buy” rating on the stock.
- 8/25/2026 – AnaptysBio was downgraded by Scotiabank to “hold”. They now have a $70.00 price target on the stock.
- 8/24/2026 – AnaptysBio had its “buy” rating reaffirmed by HC Wainwright. They now have a $95.00 price target on the stock.
- 8/7/2026 – AnaptysBio had its “sell (e+)” rating reaffirmed by Weiss Ratings.
Insider Buying and Selling at AnaptysBio
In related news, Director Hollings Renton sold 5,000 shares of the stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $49.87, for a total transaction of $249,350.00. Following the sale, the director owned 10,995 shares in the company, valued at approximately $548,320.65. This trade represents a 31.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 31.50% of the company’s stock.
AnaptysBio, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for inflammatory and autoimmune diseases. The company uses its antibody discovery and engineering capabilities to identify therapies designed to modulate immune-system targets involved in disease.
AnaptysBio’s pipeline has included rosnilimab, an investigational antibody designed to target CD200R1, a receptor involved in regulating immune-cell activity. The company has evaluated rosnilimab in inflammatory and autoimmune conditions, including rheumatoid arthritis and ulcerative colitis.